I. Proteasome inhibitor for treatment of multiple myeloma
Murakami, H.; Saito, T.; Handa, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(5): 583-588
2013
ISSN/ISBN: 0385-0684 PMID: 23957065 Document Number: 666480
Document emailed within 1 workday
Related Documents
Kanagasabaphy, P.; Morgan, G.J.; Davies, F.E. 2007: Proteasome inhibition and multiple myeloma Current Opinion in Investigational Drugs 8(6): 447-451Richardson, P.G. 2014: Update on proteasome inhibitors in multiple myeloma Clinical Advances in Hematology and Oncology: H&o 12(3): 179-181
García Laraña, J.; Díaz Mediavilla, J.; Martínez, R.; Lahuerta, J.J.; Alegre, A.; Odriozola, J.; Sureda, A.; San Miguel, J.; De la Rubia, J.; Escudero, A.; Conde, E.; Bladé, J.; Cabrera, R.; Gastearena, J.; Besalduch, J.; Vidal, M.J.; Hernández, F.; Rifon, J.; Leon, A.; Mataix, R.; Parody, R.; Moraleda, J.M.; Solano, C.; de Pablos, J.M.; Sánchez, J.J. 1997: Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma Sangre 42(Suppl 1): 38-41
Smith, J.D.; Nobiletti, J.; Freed, M.; Malkus, H.; Donabedian, R. 1992: Interference with the Astra 8 and Synchron CX3 assays of urea nitrogen in serum by a high-M(r) inhibitor in a patient with multiple myeloma Clinical Chemistry 38(4): 598-599
Weber, D.M. 2003: Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation Oncology 17(6): 765-767
Pleban, E.; Bury, M.; Młynarczuk, I.; Wójcik, C. 2001: Effects of proteasome inhibitor PSI on neoplastic and non-transformed cell lines Folia Histochemica et Cytobiologica 39(2): 133-134
Wójcik, C. 1997: An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines Folia Histochemica et Cytobiologica 35(4): 211-214
Fu, Y.-b.; Sun, Q.-x.; Meng, F.-y.; Xie, J.; Zhou, G.-b. 2006: Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor Zhonghua Yi Xue Za Zhi 86(34): 2413-2416
Brouet, J.C. 1993: Treatment of multiple myeloma La Revue du Praticien 43(3): 321-325
Nau, K.C.; Lewis, W.D. 2008: Multiple myeloma: diagnosis and treatment American Family Physician 78(7): 853-859
Berenson, J.R. 2012: Updates in the treatment of multiple myeloma Clinical Advances in Hematology and Oncology: H&o 10(10): 667-669
Riccardi, A.; Merlini, G.; Montecucco, C.; Perugini, S. 1980: Vincristine in the treatment of multiple myeloma Haematologica 65(5): 595-611
Pasqualetti, P.; Casale, R.; Collacciani, A.; Colantonio, D. 1989: Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma Medicina 9(3): 280-282
Barlogie, B.; Alexanian, R. 1989: Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma Cancer Research 49(24 Pt 1): 7172-7175
Wu, M-Jei.; Fang, H-Chang.; Chang, T-Yuan.; Lo, Y-Shing.; Chung, H-Min. 2002: Multiple myeloma with myeloma nephropathy in a patient with Hashimoto's thyroiditis Journal of the Formosan Medical Association 101(6): 421-424
Adam, Z.; Krejcí, M.; Tichý, M.; Stepánková, S.; Pour, L.; Hájek, R. 2009: The treatment of renal failure in multiple myeloma Vnitrni Lekarstvi 55(6): 570-582
Lokhorst, H.M.; Sonneveld, P.; Wijermans, P.W.; Segeren, C.M. 1998: Multiple myeloma; treatment in the year 1998 Nederlands Tijdschrift Voor Geneeskunde 142(28): 1596-1602
2009: Treatment of multiple myeloma: 2009 update Prescrire international 18(104): 263-266
Mendez-Lopez, M.; Sutter, T.; Driessen, C.; Besse, L. 2019: HIV protease inhibitors for the treatment of multiple myeloma Clinical Advances in Hematology and Oncology: H&o 17(11): 615-623
Gotoh, A.; Ohyashiki, K. 2007: Role of bortezomib in the treatment of multiple myeloma Nihon Rinsho. Japanese Journal of Clinical Medicine 65(12): 2309-2314